Form 4: Insulet Director Michael Minogue Receives Annual Equity Award of Restricted Stock Units

Insulet Corporation Director Michael R. Minogue was granted 778 restricted stock units as part of his annual equity compensation, vesting in full on April 30, 2026.

Summary

• Michael R. Minogue, a Director of Insulet Corporation (PODD), acquired 778 shares of common stock on May 22, 2025.
• The acquisition was an annual equity award in the form of restricted stock units (RSUs), granted at a price of $0 per share.
• These RSUs will be settled on a one-for-one basis in shares of common stock.
• The RSUs are scheduled to vest in full on April 30, 2026.
• Following this transaction, Michael R. Minogue directly beneficially owns 2,158 shares of common stock.
• Additionally, he indirectly beneficially owns 9,459 shares through a GRAT and 4,614 shares through a Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event (expected), which is positive for the director receiving the award and generally seen as a standard practice for aligning interests. There are no negative financial implications or risks beyond the inherent market risk of holding equity.

Positives

• The grant of restricted stock units to Director Michael R. Minogue aligns his interests with long-term shareholder value through equity compensation.
• The transaction represents a routine annual equity award, indicating standard corporate governance and compensation practices.

Risks

• The value of the restricted stock units is subject to the future performance of Insulet Corporation's common stock until the vesting date of April 30, 2026.

Future Outlook

The 778 restricted stock units granted to Director Michael R. Minogue are scheduled to vest in full on April 30, 2026, indicating a future increase in his direct beneficial ownership of Insulet common stock upon settlement.

Industry Context

This Form 4 filing is a standard disclosure of an insider equity transaction, common across publicly traded companies as part of their executive and director compensation programs. It reflects a routine grant of restricted stock units, a common incentive mechanism in the medical device and healthcare technology sectors to retain and motivate key personnel.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as part of director compensation is a common practice across the medical technology and broader S&P 500 companies, aligning director incentives with long-term shareholder value.
• Companies like Medtronic (MDT) and Abbott Laboratories (ABT) also frequently utilize RSU grants for their directors and executives as a component of their annual compensation packages, often with multi-year vesting schedules similar to Insulet's.

Related Party Transactions

• The acquisition of 778 restricted stock units by Director Michael R. Minogue represents an equity award from Insulet Corporation, which is a standard form of compensation for a related party (company director).

Stakeholder Impact

• Shareholders: The grant of RSUs represents a minor potential future dilution upon vesting, but it is part of a standard compensation structure designed to align director interests with long-term shareholder value.
• Director Michael R. Minogue: His equity stake in Insulet Corporation will increase upon the vesting of these RSUs, further aligning his personal financial interests with the company's performance.

Next Steps

• The 778 restricted stock units granted to Michael R. Minogue are expected to vest on April 30, 2026, at which point they will convert into shares of Insulet common stock.

Key Dates

Keywords

Insulet Corporation, PODD, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, equity award, director compensation, beneficial ownership